A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

NCT02505334 · Completed

Last updated 2026-05-28

This clinical trial compares two different daily doses of liraglutide in adults with type 2 diabetes to see how they affect blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 635 people

Who can join Ages 20+ · all sexes

Timeline Started 2015-07 · est. completion 2017-11

Where 47 sites · Japan

What this study is testing ClinicalTrials.gov NCT02505334 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.

Treatments tested

liraglutide Drug

Injected subcutaneously s.c. (under the skin) once daily.

Main thing measured	Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02505334 ↗